Bjud in dina vänner/följare
Du har inga fler vänner att bjuda in
Handla om
About: Developing breakthrough medications for heart failure with preserved ejection fraction (HFpEF). Our lead drug reduced hospitalizations by 37% in Phase 3 trials.
Pipeline:
CardioPro™ - HFpEF treatment (Phase 3 complete)
RegenHeart™ - Cardiac tissue regeneration (Phase 2)
LipidShield™ - Novel cholesterol management (Phase 2)
Recent Update: "CardioPro shows unprecedented results in diabetic heart failure"
Trials Enrolling: 1,200 patients needed across 8 studies
